COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Name:
Bonifacius et al.pdf
Size:
5.738Mb
Format:
PDF
Description:
free file from the PubMedCentral ...
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Bonifacius, AgnesTischer-Zimmermann, Sabine
Dragon, Anna C
Gussarow, Daniel
Vogel, Alexander
Krettek, Ulrike
Gödecke, Nina
Yilmaz, Mustafa
Kraft, Anke R M
Hoeper, Marius M
Pink, Isabell
Schmidt, Julius J
Li, Yang
Welte, Tobias
Maecker-Kolhoff, Britta
Martens, Jörg
Berger, Marc Moritz
Lobenwein, Corinna
Stankov, Metodi V
Cornberg, Markus
David, Sascha
Behrens, Georg M N
Witzke, Oliver
Blasczyk, Rainer
Eiz-Vesper, Britta
Metadata
Show full item recordAbstract
Cellular and humoral immunity to SARS-CoV-2 is critical to control primary infection and correlates with severity of disease. The role of SARS-CoV-2-specific T cell immunity, its relationship to antibodies, and pre-existing immunity against endemic coronaviruses (huCoV), which has been hypothesized to be protective, were investigated in 82 healthy donors (HDs), 204 recovered (RCs), and 92 active COVID-19 patients (ACs). ACs had high amounts of anti-SARS-CoV-2 nucleocapsid and spike IgG but lymphopenia and overall reduced antiviral T cell responses due to the inflammatory milieu, expression of inhibitory molecules (PD-1, Tim-3) as well as effector caspase-3, -7, and -8 activity in T cells. SARS-CoV-2-specific T cell immunity conferred by polyfunctional, mainly interferon-γ-secreting CD4+ T cells remained stable throughout convalescence, whereas humoral responses declined. Immune responses toward huCoV in RCs with mild disease and strong cellular SARS-CoV-2 T cell reactivity imply a protective role of pre-existing immunity against huCoV.Citation
Immunity. 2021 Feb 9;54(2):340-354.e6. doi: 10.1016/j.immuni.2021.01.008.Affiliation
CiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.Publisher
Elsevier (Cell Press)Journal
ImmunityPubMed ID
33567252PubMed Central ID
PMC7871825Additional Links
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871825/Type
ArticleLanguage
enEISSN
1097-4180ae974a485f413a2113503eed53cd6c53
10.1016/j.immuni.2021.01.008
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Related articles
- Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension.
- Authors: Zeng Q, Li YZ, Dong SY, Chen ZT, Gao XY, Zhang H, Huang G, Xu Y
- Issue date: 2020
- Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.
- Authors: Ansari A, Arya R, Sachan S, Jha SN, Kalia A, Lall A, Sette A, Grifoni A, Weiskopf D, Coshic P, Sharma A, Gupta N
- Issue date: 2021
- SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors.
- Authors: Shomuradova AS, Vagida MS, Sheetikov SA, Zornikova KV, Kiryukhin D, Titov A, Peshkova IO, Khmelevskaya A, Dianov DV, Malasheva M, Shmelev A, Serdyuk Y, Bagaev DV, Pivnyuk A, Shcherbinin DS, Maleeva AV, Shakirova NT, Pilunov A, Malko DB, Khamaganova EG, Biderman B, Ivanov A, Shugay M, Efimov GA
- Issue date: 2020 Dec 15
- Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients.
- Authors: Ni L, Cheng ML, Feng Y, Zhao H, Liu J, Ye F, Ye Q, Zhu G, Li X, Wang P, Shao J, Deng YQ, Wei P, Chen F, Qin CF, Wang G, Li F, Zeng H, Dong C
- Issue date: 2021
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
- Authors: Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, Flaxman A, Wright D, Bellamy D, Bittaye M, Dold C, Provine NM, Aboagye J, Fowler J, Silk SE, Alderson J, Aley PK, Angus B, Berrie E, Bibi S, Cicconi P, Clutterbuck EA, Chelysheva I, Folegatti PM, Fuskova M, Green CM, Jenkin D, Kerridge S, Lawrie A, Minassian AM, Moore M, Mujadidi Y, Plested E, Poulton I, Ramasamy MN, Robinson H, Song R, Snape MD, Tarrant R, Voysey M, Watson MEE, Douglas AD, Hill AVS, Gilbert SC, Pollard AJ, Lambe T, Oxford COVID Vaccine Trial Group.
- Issue date: 2021 Feb